Carzenide
Carzenide (4-Sulfamoylbenzoic acid) is the major circulating metabolite of Mafenide in plasma. Carzenide is a strong CAII competitive inhibitor. Carzenide can be used in the research of epilepsy and cervical cancer[1][2][3].
Product Specifications
CAS Number
138-41-0
Product Name Alternative
4-Sulfamoylbenzoic acid
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Carbonic Anhydrase; Drug Metabolite
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Cancer; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/Carzenide.html
Purity
99.86
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(O)C1=CC=C(S(=O)(N)=O)C=C1
Molecular Formula
C7H7NO4S
Molecular Weight
201.20
Precautions
H302, H315, H319, H335
References & Citations
[1]Weisdorf DJ, et al. Mafenide (Sulfamylon) inhibits plasmin fibrinolytic activity. Thromb Haemost. 1988 Jun 16;59 (3) :440-4. PMID: 2973151. |[2]Zhang F, et al. Imaging of Carbonic Anhydrase Level in Epilepsy with an Environment-Sensitive Fluorescent Probe. Anal Chem. 2023 Oct 10;95 (40) :14833-14841.|[3]Abo-Ashour MF, et al. Novel synthesized SLC-0111 thiazole and thiadiazole analogues: Determination of their carbonic anhydrase inhibitory activity and molecular modeling studies. Bioorg Chem. 2019 Jun;87:794-802.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
CA II
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
HOGG11-P 100 µg
Human 8-Oxoguanine DNA Glycosylase (hOGG1) Control/blocking peptide #1
Sign In for Pricing
View Details